Efficacy and Safety Study as Monotherapy of Satralizumab (SA237) to Treat NMO and NMOSD
Lay Description
By examining the health status of patients with cystic fibrosis annually, valuable information has (and will continue) to be gained about the trends in nutrition, medical problems, lung transplantation and bacterial colonization in patients with cystic fibrosis. Collection and analysis of this information (which is collected on every CF patient in North America) allows CF care teams to improve in their knowledge of the disease and to change the way they care for patients with CF appropriately.
Category
- Lungs, Breathing and Bronchial
- IRB Number
- 20020383HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Between 18 Years and 74 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Meilinh Thi
210-567-5792
thi@uthscsa.edu
Principal Investigator
Donna Willey-Courand